PCSK-9 Inhibitors for Hyperlipidemia: Comparative Clinical Effectiveness


( Last Updated : May 8, 2017)
Project Line:
Reference List
Project Sub Line:
Reference List
Project Number:
RA0906-000

Details


Question

  1. What is the comparative clinical effectiveness of evolocumab versus alirocumab for the treatment of adults with heterozygous familial hyperlipidemia (HeFH) on maximally tolerated statin therapy who require additional lowering of low density lipoprotein cholesterol (LDL-C)?
  2. What is the comparative clinical effectiveness of evolocumab versus alirocumab for the treatment of adults with clinical atherosclerotic cardiovascular disease (CVD) on maximally tolerated statin therapy who require additional lowering of low density lipoprotein cholesterol (LDL-C)?

Key Message

Four systematic reviews, three systematic reviews with meta-analysis, and one non-randomized study were identified regarding PCSK-9 inhibitors for hyperlipidemia.